Starting Naltrexone After Opioids: Why the Opioid-Free Interval Matters
Naltrexone can trigger severe withdrawal if opioids are still present. The minimum interval is not a self-assessment rule and may be longer after buprenorphine or methadone.
Why naltrexone is different
Naltrexone blocks opioid receptors rather than activating them. That mechanism is useful for alcohol use disorder and for relapse prevention after opioid detoxification, but it can rapidly displace opioids from the receptors of someone who is physically dependent. The resulting precipitated withdrawal is different from ordinary withdrawal that follows stopping opioids. Both the Vivitrol and oral naltrexone labels describe this risk.
Both the oral naltrexone and Vivitrol labels describe precipitated withdrawal severe enough in some cases to require hospital or intensive-care management. That is why the opioid-free interval is a safety requirement, not a test of willpower or a fixed schedule to follow without clinical support.
What the 7–10-day minimum means
For people previously dependent on short-acting opioids, the US labels recommend a minimum opioid-free interval of 7–10 days before naltrexone. The exact timing depends on the opioid, formulation, dose, pattern of use, and individual metabolism.
The interval can be longer after buprenorphine, buprenorphine/naloxone, or methadone. The labels warn that people switching from these medicines may be vulnerable to precipitated withdrawal for up to two weeks. There are not enough systematically collected data to turn that warning into a universal calendar rule.
Does naltrexone require “full opioid detoxification”?
For opioid use disorder, Vivitrol is indicated after opioid detoxification, and both US labels require the clinician to establish an adequate opioid-free interval before starting naltrexone. “Full detoxification” is not a reliable do-it-yourself calendar term: the answer depends on the opioid and the person’s current symptoms and history. Naltrexone is not the only medicine used in opioid use disorder, so a comparison question should not be used to change or stop another treatment without the prescribing team.
Opioids that can be missed in a medication history
The prescriber needs the complete history, including opioid pain medicine, tramadol, buprenorphine, methadone, non-prescribed opioids, and opioid-containing medicines for cough, cold, or diarrhoea. This review is needed even when naltrexone is being started for alcohol use disorder.
Never withhold or alter that history to accelerate treatment. The safer plan may involve a different timing, closer monitoring, another treatment option, or a supported transition.
Naloxone challenge testing: useful but not definitive
A clinician may consider a naloxone challenge test when there is doubt about hidden opioid dependence. The oral-tablet label states that no method completely proves that the opioid-free interval is adequate: precipitated withdrawal has occurred despite a negative urine screen or a tolerated naloxone challenge, particularly after buprenorphine treatment.
The test should not be performed in a person showing clinical opioid withdrawal or with opioid-positive urine. It is a clinician-administered assessment—not a home test and not a guarantee that naltrexone can be started safely.
Questions to resolve before the first dose or injection
- What was the last use of every opioid-containing medicine or substance?
- Was the opioid short-acting, long-acting, buprenorphine, or methadone?
- Are there current signs of withdrawal or any uncertainty about opioid exposure?
- Does the exact label call for testing or a different transition plan?
- What support is available if withdrawal, relapse risk, or overdose risk changes during the transition?
The interval does not remove every opioid-related risk
Naltrexone reduces opioid tolerance. Vivitrol’s label warns that overdose can occur at the end of a dosing interval, after a missed dose, or after treatment is stopped; trying to overcome receptor blockade with a large opioid dose can also be fatal. The treatment team should discuss access to an opioid-overdose reversal agent and emergency planning with the patient and people close to them.
Primary sources
- DailyMed: Vivitrol prescribing information
US label, revised December 2025; opioid-free interval, buprenorphine/methadone transition, and overdose warnings.
- DailyMed: naltrexone hydrochloride tablet prescribing information
US oral-tablet label; precipitated withdrawal and naloxone challenge limitations.